Akeso Biopharma Closes on $150M Series D Private Financing

Akeso Biopharma has completed Series D Financing of nearly 150 million dollars, led by Loyal Valley Capital and Sino Biopharmaceutical, with participation from famed investment institutions including Shenzhen Capital Group, Lake Bleu Healthcare Fund, CDG International Company, AIHC master fund, Orbimed, K. Wah Group, CCB Capital Management, Apricot Capital, Triwise Capital and BOCOM International Holdings. 

Dr. Xia Yu, CEO, President, and founder of Akeso said, "After this round of financing is completed, to further develop and expand the company, we will accelerate the R&D of innovative drugs pipelines and the clinical trials of new drug programs, attract and nurture talent, and further quicken the entry of high-quality, innovative medicines into the market through self-R&D and external collaborations."

Akeso Biopharma is an innovative biotechnology company headquartered at the National Health Technology Park of Zhongshan Torch Development Zone in Guangdong province. Akeso Biopharma focuses on discovering and developing self-develop new-generation world-leading novel antibody drugs for the treatment of a broad spectrum of diseases. Founded in March 2012 and led by a member of China’s 1000 Talents Program, the company has developed a product portfolio consisting of over 30 drugs being researched in the anti-tumor and self-immunological fields. 

The unique Tetrabody bi-functional antibody development technology developed by Akeso Biopharma has become one of the few double-resistance platforms with production and clinical verification. The company has also developed through Tetrabody technology a series of bi-functional antibody drugs based on PD-1. 

Founded in 2015 by Andy Lin, LVC is a thematic, research-driven private equity firm with a strong entrepreneurial culture that invests in middle-market companies positioned to benefit from secular industry transformation in China. With over $1.3 billion of committed capital, LVC mainly focuses on the following segments: New Consumer (Media, Entertainment and Education), Healthcare and also covers Specialty Industrials and Financial Services. 

OrbiMed Capital is an investment firm dedicated exclusively to the healthcare sector. It invests globally across a spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed Capital manages a series of private equity funds, public equity funds, royalty/debt funds, and other investment vehicles.